Zevor-cel (Zevorcabtagene autoleucel) is a BCMA chimeric antigen receptor (CAR) T-cell therapy. This innovative treatment is used primarily for multiple myeloma.
Zevor-cel has been approved by the China National Medical Products Administration (NMPA) for indications:
Adult patients with relapsed or refractory multiple myeloma who have previously progressed after at least 3 lines of therapy (including a proteasome inhibitor and immunomodulator agent).
Ask your doctor if Zevor-cel is an option for you.
The approval of zevor-cell is based on an open-label, single arm, multi-center Phase II clinical trial (LUMMICAR STUDY 1, NCT03975907) conducted in China. The trial results were released at the 2022 Annual Meeting of the American Society of Hematology (“ASH”), and zevorcabtagene autoleucel demonstrated encouraging efficacy and a favorable safety profile.
Please note that the data above comes from the clinical study, individual patient may have different results of treatment in the clinical practice based on multiple factors, including physical condition, disease status, T cell function and so on. It is recommended that you can consult your doctor if you have specific questions.
China has experienced remarkable growth in the field of medicine over the past few decades, reflecting its broader advancements in science and technology. The country has made substantial investments in healthcare infrastructure, research, and development, which have significantly improved its medical capabilities. Cutting-edge facilities, increased funding for biomedical research, and a focus on innovation have enabled China to make strides in various areas of medicine, including CAR T-cell therapy.
CAR T-cell therapy has seen substantial progress in China, with several therapies approved for treating blood cancers like large B-cell lymphoma, acute lymphoblastic leukemia and multiple myeloma. The NMPA has streamlined approval processes, and domestic companies are actively developing new therapies and reducing costs. Research and clinical trials are vibrant, focusing on improving efficacy and managing side effects. China is making significant strides in expanding the availability and innovation of CAR T-cell therapies.
China has made significant strides in medical care and research, including advancements in CAR T-cell therapy.
China’s rapid advancements in biotechnologies are establishing it as a leader in CAR T-cell therapy, ensuring effective treatments.
China offers effective CAR T-cell therapies and other medical services with patient-friendly pricing and an accessible approach.
Our devoted service team is with you every step of the way during the CAR T-cell treatment, providing support as you combat cancer.
In China, Zevor-cel is only provided at certified treatment centers, these centers/hospitals usually are leading hospitals in the region, where the medical staff are highly skilled in managing lymphoma, and are specially trained to take care of you during the entire CAR T-cell therapy process.
You should plan to stay at the certified treatment center for at least one week following the infusion, and you’ll have several appointments before and after the treatment. Your treatment team will advise you on how close you need to be to a certified healthcare facility during the first four weeks after the infusion.
